acid zoledronic polipharma 4 mg/5 ml
polipharma industries s.r.l. - acidum zoledronicum - conc. pt. sol. perf. - 4mg/5ml - med. ce influenteaza in structura osoasa si mineralizare bifosfonati
acid zoledronic polipharma 5 mg
polipharma industries s.r.l. - acidum zoledronicum - sol. perf. - 5mg - med. ce influenteaza in structura osoasa si mineralizare bifosfonati
meropenem aptapharma 1000 mg
acs dobfar s.p.a. - italia - meropenemum - pulb. pt. sol. inj./perf. - 1000mg - alte antibiotice betalactamice carbapeneme
meropenem aptapharma 500 mg
acs dobfar s.p.a. - italia - meropenemum - pulb. pt. sol. inj./perf. - 500mg - alte antibiotice betalactamice carbapeneme
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - clopidogrel clorhidrat - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agenți antitrombotici - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
memantine lek
pharmathen s.a. - memantină clorhidrat - boala alzheimer - psychoanaleptics, , alte medicamente pentru tratamentul demenței - tratamentul pacienților cu boală alzheimer moderată până la severă.
zoledronic acid teva pharma
teva b.v. - acid zoledronic - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - medicamente pentru tratamentul bolilor osoase - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. tratamentul de boala paget osoase la adulți.
vancomicina pharmaswiss 500 mg
pharmaswiss ceska republika s.r.o. - vancomycinum - pulb. pt. sol. perf. - 500mg - alte antibacteriene antibacteriene glicopeptidice
vancomicina pharmaswiss 1000 mg
pharmaswiss ceska republika s.r.o. - vancomycinum - pulb. pt. sol. perf. - 1000mg - alte antibiotice antibiotice glicopeptidice
moxifloxacina pharmathen 5 mg/ml
pharmathen s.a. - moxifloxacinum - pic. oft., sol. - 5mg/ml - antiinfectioase alte antiinfectioase